利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

24 条记录 (耗时 0.022 秒)

    SPARC-DERIVED TUMOR REJECTION ANTIGENIC PEPTIDES AND MEDICAMENTS COMPRISING THE SAME
    1.
    发明申请
    SPARC-DERIVED TUMOR REJECTION ANTIGENIC PEPTIDES AND MEDICAMENTS COMPRISING THE SAME 有权
    SPARC衍生的肿瘤抑制抗原肽和包含其的药物

    公开(公告)号：US20100152421A1

    公开(公告)日：2010-06-17

    申请号：US12304350

    申请日：2007-06-15

    申请人： Yasuharu Nishimura ,  Yoshiaki Ikuta ,  Shuichi Nakatsuru

    发明人： Yasuharu Nishimura ,  Yoshiaki Ikuta ,  Shuichi Nakatsuru

    IPC分类号： C07K7/06 ,  C07K16/30 ,  C12N5/0783

    CPC分类号： C07K7/06 ,  A61K38/00 ,  A61K39/0011 ,  A61K2039/5154 ,  C07K14/47 ,  C07K16/18

    摘要： It is an objective of the present invention to identify SPARC protein-derived peptides that are able to induce human killer T cells and helper T cells having cytotoxic activity to tumors, and to provide a means for carrying out a tumor immunotherapy of patients with various types of cancers overexpressing SPARC. The present invention provides a peptide of any of the following: (A) a peptide which consists of the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3; or (B) a peptide which consists of an amino acid sequence comprising a substitution or addition of one or several amino acids with respect to the peptide consisting of the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3, and which has capacity to induce cytotoxic (killer) T cells.

    摘要翻译： 本发明的目的是鉴定能够诱导人类杀伤T细胞和对肿瘤具有细胞毒性活性的辅助性T细胞的SPARC蛋白衍生肽，并提供用于对各种类型的患者进行肿瘤免疫治疗的手段 的过表达SPARC的癌症。 本发明提供以下任一项的肽：（A）由SEQ ID NO：1〜3中任一项所示的氨基酸序列构成的肽; 或（B）由包含相对于由SEQ ID NO：1至3中任一项所示的氨基酸序列组成的肽取代或添加一个或数个氨基酸的氨基酸序列组成的肽，以及 其具有诱导细胞毒性（杀伤）T细胞的能力。

    SPARC-derived tumor rejection antigenic peptides and medicaments comprising the same
    2.
    发明授权
    SPARC-derived tumor rejection antigenic peptides and medicaments comprising the same 有权
    SPARC衍生的肿瘤排斥抗原肽和包含其的药物

    公开(公告)号：US08053557B2

    公开(公告)日：2011-11-08

    申请号：US12304350

    申请日：2007-06-15

    申请人： Yasuharu Nishimura ,  Yoshiaki Ikuta ,  Shuichi Nakatsuru

    发明人： Yasuharu Nishimura ,  Yoshiaki Ikuta ,  Shuichi Nakatsuru

    IPC分类号： A61K38/08

    CPC分类号： C07K7/06 ,  A61K38/00 ,  A61K39/0011 ,  A61K2039/5154 ,  C07K14/47 ,  C07K16/18

    摘要： It is an objective of the present invention to identify SPARC protein-derived peptides that are able to induce human killer T cells and helper T cells having cytotoxic activity to tumors, and to provide a means for carrying out a tumor immunotherapy of patients with various types of cancers overexpressing SPARC. The present invention provides a peptide of any of the following: (A) a peptide which consists of the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3; or (B) a peptide which consists of an amino acid sequence comprising a substitution or addition of one or several amino acids with respect to the peptide consisting of the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3, and which has capacity to induce cytotoxic (killer) T cells.

    摘要翻译： 本发明的目的是鉴定能够诱导人类杀伤T细胞和对肿瘤具有细胞毒性活性的辅助性T细胞的SPARC蛋白衍生肽，并提供用于对各种类型的患者进行肿瘤免疫治疗的手段 的过表达SPARC的癌症。 本发明提供以下任一项的肽：（A）由SEQ ID NO：1〜3中任一项所示的氨基酸序列构成的肽; 或（B）由包含相对于由SEQ ID NO：1至3中任一项所示的氨基酸序列组成的肽取代或添加一个或数个氨基酸的氨基酸序列组成的肽，以及 其具有诱导细胞毒性（杀伤）T细胞的能力。

    NOVEL DIAGNOSTIC KIT FOR MALIGNANT MELANOMA
    5.
    发明申请
    NOVEL DIAGNOSTIC KIT FOR MALIGNANT MELANOMA 失效
    用于恶性肿瘤的新型诊断试剂盒

    公开(公告)号：US20090111095A1

    公开(公告)日：2009-04-30

    申请号：US11577435

    申请日：2005-08-09

    申请人： Yasuharu Nishimura ,  Tetsuya Nakatsura ,  Yoshiaki Ikuta

    发明人： Yasuharu Nishimura ,  Tetsuya Nakatsura ,  Yoshiaki Ikuta

    IPC分类号： C12Q1/68 ,  C07K16/18

    CPC分类号： G01N33/5743 ,  G01N2333/4722 ,  G01N2333/4727

    摘要： The object of the present invention is to find out another tumor marker which is useful for early diagnosis of melanoma, and provide a diagnostic kit and diagnostic method for malignant melanoma using such marker. The present invention provides a diagnostic kit for malignant melanoma, which comprises an antibody against SPARC and an antibody against GPC3.

    摘要翻译： 本发明的目的是找出可用于黑色素瘤早期诊断的另一种肿瘤标志物，并提供使用这种标记物的恶性黑素瘤的诊断试剂盒和诊断方法。 本发明提供了用于恶性黑素瘤的诊断试剂盒，其包含针对SPARC的抗体和针对GPC3的抗体。

    IMP-3 OLIGOPEPTIDES AND VACCINES INCLUDING THE SAME
    7.
    发明申请
    IMP-3 OLIGOPEPTIDES AND VACCINES INCLUDING THE SAME 审中-公开
    IMP-3寡核苷酸和疫苗，包括它们

    公开(公告)号：US20120308590A1

    公开(公告)日：2012-12-06

    申请号：US13513120

    申请日：2010-11-30

    申请人： Yasuharu Nishimura ,  Michiko Harao ,  Yusuke Tomita ,  Yusuke Nakamura ,  Takuya Tsunoda

    发明人： Yasuharu Nishimura ,  Michiko Harao ,  Yusuke Tomita ,  Yusuke Nakamura ,  Takuya Tsunoda

    IPC分类号： A61K39/00 ,  C07H21/04 ,  A61K31/7088 ,  A61P35/00 ,  A61K35/14 ,  C07K7/06 ,  C12N5/078

    CPC分类号： A61K39/0011 ,  A61K2039/5154 ,  A61K2039/5156 ,  A61K2039/57 ,  C07K14/47

    摘要： Oligopeptides having cytotoxic T cell inducibility and suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines are described herein. Notable examples include oligopeptides having the amino acid sequence of SEQ ID NO: 1, 3, 5 or 6, wherein 1, 2, or several amino acids are optionally substituted, deleted, inserted or added so long as they retain the cytotoxic T cell inducibility of the original oligopeptides. Pharmaceutical formulations or “drugs” related to such oligopeptides suitable for treating or preventing cancers or tumors, as well as the post-operative recurrence thereof, are also described.

    摘要翻译： 本文描述了具有细胞毒性T细胞诱导能力并且适用于癌症免疫治疗，尤其是癌症疫苗的背景下的寡肽。 值得注意的实例包括具有SEQ ID NO：1,3,5或6的氨基酸序列的寡肽，其中1,2或几个氨基酸任选被取代，缺失，插入或加入，只要它们保留细胞毒性T细胞诱导性即可 的原始寡肽。 还描述了与适用于治疗或预防癌症或肿瘤的这种寡肽相关的药物制剂或药物，以及其术后复发。

    Cancer antigen and use thereof
    10.
    发明申请
    Cancer antigen and use thereof 有权
    癌症抗原及其用途

    公开(公告)号：US20090074800A1

    公开(公告)日：2009-03-19

    申请号：US12155864

    申请日：2008-06-11

    申请人： Tetsuya Nakatsura ,  Yasuharu Nishimura

    发明人： Tetsuya Nakatsura ,  Yasuharu Nishimura

    IPC分类号： A61K39/00 ,  A61P35/04

    CPC分类号： G01N33/57419 ,  A61K39/00 ,  C07K14/4748 ,  G01N33/57438

    摘要： An object of the present invention to provide: a human pancreatic cancer antigen and/or a human colon cancer antigen that can be applied to the diagnosis and/or treatment of various types of cancers or tumors including pancreatic cancer and colon cancer as representative examples; a gene encoding the same; an anti-cancer vaccine using the same; or the like. The present invention provides a cancer antigen comprising a protein having the amino acid sequence shown in SEQ ID NO: 1; a peptide comprising a portion of said protein and having immune-stimulating activity; an anti-cancer vaccine comprising said peptide; a DNA having the nucleotide sequence shown in SEQ ID NO: 2, or its complementary sequence or a part or full length of these sequence; an anti-cancer vaccine comprising said DNA; and use thereof.

    摘要翻译： 本发明的目的是提供：可用于诊断和/或治疗包括胰腺癌和结肠癌的各种类型的癌症或肿瘤的人胰腺癌抗原和/或人结肠癌抗原作为代表性实例; 编码该基因的基因; 使用其的抗癌疫苗; 或类似物。 本发明提供包含具有SEQ ID NO：1所示氨基酸序列的蛋白质的癌抗原; 包含所述蛋白质的一部分并具有免疫刺激活性的肽; 包含所述肽的抗癌疫苗; 具有SEQ ID NO：2所示核苷酸序列的DNA或其互补序列或这些序列的部分或全长; 包含所述DNA的抗癌疫苗; 及其用途。